Roots Analysis Identifies Six Leading Plasma Fractionation Companies
Roots Analysis has identified six prominent companies in the plasma fractionation market. Rising prevalence of rare diseases and demand for plasma-derived therapies necessitate advancements in the sector.
A report released by Roots Analysis in January 2023 identifies six key players in the global plasma fractionation market. The publication highlights the sector's critical role in producing blood-derived therapies used to treat rare and chronic diseases. Increasing demand for these therapies is driving market expansion.
The analysis examined over 35 companies capable of performing plasma fractionation, either in-house or through contract services. The six leading companies identified are Baxter, CSL, Grifols, Kedrion, Octapharma, and Takeda Pharmaceutical Company. These companies are major players with plasma fractionation facilities in multiple regions.
The use of blood plasma for therapeutic purposes dates back over a century, with significant advancements made during World War II. Today, over 95 plasma-derived therapies have been approved, and companies in the sector are taking initiatives, including investments in new manufacturing facilities and partnerships, to meet the growing demand.
The market is expected to experience steady growth in the coming years. Potential for expansion is particularly noted in the African and Asian markets. Emerging technologies, such as medical drones for delivery, may enhance access to plasma products in remote areas in the future.
The Roots Analysis report provides a detailed overview of the current market landscape and future opportunities for companies in the plasma fractionation sector over a 12-year period.